icon- folder.gif   Conference Reports for NATAP  
 
  4th IAS (Intl AIDS Society) Conference on HIV Pathogenesis, Treatment and Prevention
Sydney, Australia
22-25 July 2007
Back grey_arrow_rt.gif
 
 
 
Efficacy and safety of switching from boosted Lopinavir (LPV/r) to boosted Atazanavir (ATV/r) in patients with virologic suppression receiving a LPV/r containing HAART: The ATAZIP study
 
 
  Reported by Jules Levin
IAS Conference 22-25 July, 2007, Sydney, Australia
 
Mallolas J.1, Podzamczer D.2, Domingo P.3, Clotet B.4, Ribera E.5, Gutierrez F.6, Knobel H.7, Cosin J.8, Ferrer E.2, Arranz J.A.9, Roca V.  10, Vidal F.13, Pe–aranda M.14, Pedrol E.15, Llibre J.M.16, Dalmau D.17, Garcia I.18, Aranda M.19, Pich J.11, de Lazzari E.12, Gatell J.M.1, for the ATAZIP study group
 
AUTHORS CONCLUDED:
Switching to ATV/r in virologically suppressed patients who were receiving a LPV/r containing HAART provided comparable efficacy (meets non-inferiority criteria) and safety profile.
 
It was associated with improved lipid parameters (triglycerides and total cholesterol).
 
See the data below: Viral failure (>200 c/ml): 5% ATV/r, 6% LPV/r. See lab abnormalities, lipids, AEs below.
 
BACKGROUND
ATV is a potent, well-tolerated, once-daily (QD) protease inhibitor (PI) extensively studied in treatment-naive and -experienced patients
 
The SWAN study (BMS 097)1 demonstrated that switching from PI ± RTV-containing regimens to an unboosted ATV-containing regimen maintained virologic suppression with improvement in plasma lipids through 48 weeks in patients without previous failures to PI containing regimens
 
However, there are limited data available on the utility of switching virologically suppressed patients from LPV/r-based regimens to a different boosted PI such as ATV/r including those with previous failures to PI containing regimens or PI associated mutations 1Gatell et al. Clin Infect Dis 2007
 
OBJECTIVE
To assess the safety and efficacy of ATV/r based HAART in virologically suppressed patients receiving a LPV/r containing regimen including patients with previous failures (< 3) to PI regimens or history of having PI associated mutations (< 5) prior to starting the LPV/r-based regimen.
 
STUDY DESIGN
265 patients stable on Kaletra based regimen for >6 months and VL <200 and <3 previous viral failures while on PI based HAART and <5 PI mutations were randomized to switch to ATV/r qd or continue Kaletra bid. The primary analysis was at week 48, final analysis at week 96.
 

Final-1.gif

PRIMARY ENDPOINT
The proportion of patients with treatment failure for any reason through Week 48 --Includes virologic rebound (> 200 cp/mL), discontinuation of study therapy or lost to follow-up, progression to a new CDC event or death.
--Non-inferiority study. Upper limit of 95% CI of estimated difference < 12.5%.
 
Secondary Endpoints
The proportion of patients with virologic rebound at or prior to Week 48 --Confirmed on-study HIV RNA ≥ 200 copies/mL or last on-study HIV RNA ≥ 200 copies/mL followed by discontinuation
 
Time to treatment failure and to virologic failure
 
Safety
 
Evolution of fasting plasma lipids
 
PLANNED SUBSTUDIES
--Metabolic (METATAZIP)
--Resistance
--QoL
--Risk factors for virological failure
 
PLANNED SUB-ANALYSIS
--Focusing on those with < 50 copies at baseline
 
--Focusing on patients with previous PI failures or history of PI resistance mutations
 

charBas-2.gif

notTest-3.gif

LPV-4.gif

Patient Disposition at month 12
Discontinuation rates 13% for those switched to ATV/r, 14% for those continuing on Kaletra: 1 for viral failure on atv/r and 1 on lpv/r; for adverse events, 6 on each arm; for Ôpatient decision, 2 on lpv/r, 0 atv/r. For patients continuing assigned therapy: discts. 5 for viral failure on ATV/r and 7 on LPV/r.
 

TimeFail-5.gif

Treatment Failure and Virologic Failure (≥ 200 c/mL) through month 12 20% treatment failure for LPV/r, 17% for ATV/r (p=0.7). Viral failure (>200 c.ml): 6% lpv/r (8/127), 5% ATV/r (6/121) (p=0.08).

month-6.gif

CD4 Changes
Median changes from baseline in CD4 cell count were similar beteween groups: +26 cells/mm3 (ATV/r) and +51 cells/mm3 (LPV/r) at month 12 (p=0.2)

ATV-7.gif

Adverse Events through month 12
There were total of 6 in each group; GI-related: 1 in ATV/r, 2 LPV/r; CNS, 1 in ATV/r, 1 in LPV/r; liver: 1 in ATV/r, 1 in LPV/r; metabolic-related: 1 in ATV/r, 4 in LPV/r; hyperbilirubinemia/jaundice: 2 in ATV/r, 0 in LPV/r; death: 0 in ATV/r, 1 in LPV/r; any AE: 61% in ATV/r, 50% in LPV/r.

Death-8.gif

LIVER LAB ABNORMALITIES
Liver function abnormalities, ALT/AST >200: 2% ALT, 2% AST for ATV/r; 1% ALT, 2% AST for LPV/r; ALT or AST: 4% ATV/r, 2% LPV/r. total bilirubin: 5% ATV/r, 2% LPV/r.
--Liver Function Abnormalities (ALT/AST >200) when ALT or AST were >40 at baseline (n=34 ATV/r, 33 LPV/r): ALT - 9% ATV/r, 6% PV/r; AST: 9% ATV/r, 6% LPV/r; ALT or AST: 12% ATV/r, 6% LPV/r.

Liver-9.gif

LIPIDS. Median values and Changes From Baseline in Lipid Parameters at month 12 --Median TG decreased on ATV/r from 181 to 145 and increased on LPV/r from 191 to 202;
--Total chol decreased on ATV/r from 202 to 193 and on LPV/r increased from 205 to 207.
--LDL-C on ATV/r increased from 107 to 111 and on LPV/r remained the same at 111.
--HDL-C changed from 50 to 46 on ATV/r and from 49 to 46 on LPV/r.

Median-10.gif

TG-11.gif

LIPIDS. Percentage above NCEP treatment recommendations at baseline and through month 12.
--TG >500: on ATV/r, 3% at baseline, 4% at mo 12 (+1%); on LPV/r, 10% at baseline, 17% at mo 12 (+7%).
--Total chol >240: on ATV/r, 23% at baseline, 20% at month 12 (-3%); on LPV/r, 20% at baseline, 26% at mo 12 (+6%);
--LDL>130: on ATV/r, 20% at baseline, 25% at mo 12 (+5%); on LPV/r, 20% at baseline, 30% at mo 12 (+10%);
--HDL-C <40: on ATV/r, 16% at baseline, 32% at mo 12 (+16%); on LPV/r, 21% at baseline, 29% at mo 12 (+8%).

Nhdl-12.gif

No significant changes were obseved in Lipid Lowering Agents (LLA) usage during the follow-up in both arms